Karason, Kristjan http://orcid.org/0000-0002-2802-1191
Girerd, Nicolas
Andersson-Asssarsson, Johanna http://orcid.org/0000-0001-9082-8589
Duarte, Kevin
Taube, Magdalena
Svensson, Per-Arne http://orcid.org/0000-0002-6731-806X
Huby, Anne-Cecile
Peltonen, Markku http://orcid.org/0000-0002-3767-4223
Carlsson, Lena M.
Zannad, Faiez
Article History
Received: 1 February 2022
Revised: 7 July 2022
Accepted: 11 July 2022
First Online: 9 August 2022
Competing interests
: KK has received lecture fees from Orion Pharma AB and Abbot. LMC has received consulting fees from Johnson & Johnson. MT holds stocks in Umecrine AB, and has a patent licensed to Umecrine AB. FZ reports steering committee personal fees from Applied Therapeutics, Bayer, Boehringer, Boston Scientific, Novartis, Janssen, Cellprothera and CVRx, advisory board personal fees from, AstraZeneca, Vifor Fresenius, Cardior, Cereno pharmaceutical, Corvidia, Merck, Myokardia, NovoNordisk and Owkin, stock options at Cereno and G3Pharmaceutical, and being the founder of CardioRenal and the Global Cardiovascular Clinical Trialist Forum. None of the remaining authors have any conflicts of interest ties to disclose.